

# Psoriasis and comorbid diseases

## Epidemiology



Junko Takeshita, MD, PhD, MSCE,<sup>a,b</sup> Sungat Grewal, BS,<sup>a</sup> Sinéad M. Langan, MB, BCh, BAO, MRCP, MSc, PhD,<sup>c</sup>  
Nehal N. Mehta, MD, MSCE,<sup>d</sup> Alexis Ogdie, MD, MSCE,<sup>b,c</sup> Abby S. Van Voorhees, MD,<sup>f</sup>  
and Joel M. Gelfand, MD, MSCE<sup>a,b</sup>

*Philadelphia, Pennsylvania; London, United Kingdom; Bethesda, Maryland; and Norfolk, Virginia*

*See related articles on pages 393 and 531*

### Learning objectives

After completing this learning activity, participants should be able to list at least five comorbidities that are associated with psoriasis, and discuss the supporting evidence and identify psoriasis patients who have the greatest risk of developing cardiovascular disease.

### Disclosures

#### Editors

The editors involved with this CME activity and all content validation/peer reviewers of the journal-based CME activity have reported no relevant financial relationships with commercial interest(s).

#### Authors

The authors involved with this journal-based CME activity have reported no relevant financial relationships with commercial interest(s).

#### Planners

The planners involved with this journal-based CME activity have reported no relevant financial relationships with commercial interest(s). The editorial and education staff involved with this journal-based CME activity have reported no relevant financial relationships with commercial interest(s).

Psoriasis is a common chronic inflammatory disease of the skin that is increasingly being recognized as a systemic inflammatory disorder. Psoriatic arthritis is a well-known comorbidity of psoriasis. A rapidly expanding body of literature in various populations and settings supports additional associations between psoriasis and cardiometabolic diseases, gastrointestinal diseases, kidney disease, malignancy, infection, and mood disorders. The pathogenesis of comorbid disease in patients with psoriasis remains unknown; however, shared inflammatory pathways, cellular mediators, genetic susceptibility, and common risk factors are hypothesized to be contributing elements. As additional psoriasis comorbidities continue to emerge, education of health care providers is essential to ensuring comprehensive medical care for patients with psoriasis. (J Am Acad Dermatol 2017;76:377-90.)

**Key words:** cardiovascular disease; chronic kidney disease; comorbidities; Crohn's disease; depression; metabolic syndrome; nonalcoholic fatty liver disease; psoriasis; psoriatic arthritis; lymphoma; infection.

From the Departments of Dermatology,<sup>a</sup> Epidemiology and Biostatistics, Center for Clinical Epidemiology and Biostatistics,<sup>b</sup> and Division of Rheumatology,<sup>c</sup> University of Pennsylvania Perelman School of Medicine, Philadelphia; London School of Hygiene and Tropical Medicine and St. John's Institute of Dermatology,<sup>c</sup> London; National Heart, Lung and Blood Institute,<sup>d</sup> Bethesda; and the Department of Dermatology,<sup>f</sup> Eastern Virginia Medical School, Norfolk.

Supported in part by National Institute of Arthritis and Musculoskeletal and Skin Diseases grants K24AR064310 (Dr Gelfand), T32AR00746532 (Ms Grewal), K23AR063764 (Dr Ogdie), and K23AR068433 (Dr Takeshita), a Dermatology Foundation Career Development Award (Dr Takeshita), the Intramural Research Program at the National Institutes of Health grant ZIAHL006193-02 (Mehta), and a National Institute for Health Research Clinician Scientist Fellowship (grant NIHR/CS/010/014 to Dr Langan). The findings and conclusions in this report are those of the authors and do not necessarily represent the views of the UK Department of Health.

Dr Takeshita has received a research grant (to the Trustees of the University of Pennsylvania) from Pfizer Inc and payment for continuing medical education work related to psoriasis. Dr Mehta is a full-time employee of the US Government. Dr Ogdie receives research grants from AbbVie (to the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis [GRAPPA]), Celgene (to GRAPPA), and Pfizer Inc (to the Trustees of the University of Pennsylvania and GRAPPA), and has served as a consultant for

Novartis, receiving honoraria. Dr Van Voorhees has served as a consultant for AbbVie, Amgen, Aqua, AstraZeneca, Celgene, Corrona, Dermira, Janssen, Leo, Novartis, and Pfizer, receiving honoraria; received a research grant from AbbVie; and has other relationship with Merck. Dr Gelfand has served as a consultant for AbbVie, AstraZeneca, Celgene Corp, Coherus, Eli Lilly, Janssen Biologics (formerly Centocor), Sanofi, Merck, Novartis Corp, Endo, and Pfizer Inc, receiving honoraria; receives research grants (to the Trustees of the University of Pennsylvania) from AbbVie, Amgen, Eli Lilly, Janssen, Novartis Corp, Regeneron, and Pfizer Inc; and received payment for continuing medical education work related to psoriasis. Dr Gelfand is a co-patent holder of resiquimod for treatment of cutaneous T-cell lymphoma. No other potential conflicts of interest were declared by the authors.

Accepted for publication July 1, 2016.

Correspondence to: Junko Takeshita, MD, PhD, MSCE, Department of Dermatology, University of Pennsylvania Perelman School of Medicine, 3400 Civic Center Boulevard, Perelman Center for Advanced Medicine, 7th Floor, South Tower, Office 728, Philadelphia, PA 19104. E-mail: [Junko.Takeshita@uphs.upenn.edu](mailto:Junko.Takeshita@uphs.upenn.edu).

0190-9622/\$36.00

© 2016 by the American Academy of Dermatology, Inc. Published by Elsevier Inc. All rights reserved.

<http://dx.doi.org/10.1016/j.jaad.2016.07.064>

**Date of release: March 2017**

**Expiration date: March 2020**

*Abbreviations used:*

BMI:	body mass index
BSA:	body surface area
CAD:	coronary artery disease
CD:	Crohn's disease
CEC:	cholesterol efflux capacity
CHD:	coronary heart disease
CKD:	chronic kidney disease
CTCL:	cutaneous T-cell lymphoma
CV:	cardiovascular
CVD:	cardiovascular disease
ESRD:	end-stage renal disease
FDG:	fluorodeoxyglucose
FRS:	Framingham Risk Score
HDL:	high-density lipoprotein
IBD:	inflammatory bowel disease
IHD:	ischemic heart disease
MACE:	major adverse cardiovascular events
MI:	myocardial infarction
NAFLD:	nonalcoholic fatty liver disease
NASH:	nonalcoholic steatohepatitis
NMSC:	nonmelanoma skin cancer
OR:	odds ratio
PET/CT:	positron emission tomography/ computed tomography
PsA:	psoriatic arthritis
RA:	rheumatoid arthritis
RR:	relative risk or risk ratio
UC:	ulcerative colitis

**INTRODUCTION**

Psoriasis is a common chronic inflammatory disease that affects >7.5 million people in the United States and approximately 125 million people worldwide.<sup>1-3</sup> It has significant impacts on both physical and emotional health-related quality of life comparable to other major illnesses.<sup>4</sup> In the last decade, tremendous progress has been made in furthering our understanding of the genetics, pathophysiology, and treatment of psoriasis. Epidemiologic and basic scientific evidence contributing to our knowledge of the natural history and biology of psoriasis, respectively, have led to the recognition of psoriasis as a disorder with important health implications that extend beyond the skin.

The first observation of comorbid disease among patients with psoriasis was made in 1897 when Strauss<sup>5</sup> reported an association between psoriasis and diabetes. In 1961, Reed et al<sup>6</sup> described a high prevalence of heart disease including coronary thrombosis and myocardial infarction (MI) in postmortem examinations of psoriasis patients with psoriatic arthritis (PsA). Subsequently, in 1978, McDonald et al<sup>7</sup> observed an increased prevalence of venous and arterial vascular disease in hospitalized patients with psoriasis. Now many years later, a quickly evolving body of literature using modern epidemiologic techniques has shown that psoriasis, particularly severe disease, is associated with increased mortality<sup>8</sup> and comorbid disease burden<sup>9,10</sup>

that are hypothesized to be the result of chronic inflammation associated with the skin disease.

We review the epidemiologic data supporting associations between psoriasis and cardiometabolic diseases, gastrointestinal diseases, kidney disease, malignancy, infection, mood disorders, PsA, and other emerging comorbid diseases. Recognition of the comorbid disease burden associated with psoriasis is essential for comprehensive medical care for patients with this chronic skin disorder.

**CARDIOMETABOLIC DISEASE****Key points**

- **Cardiometabolic disease is prevalent among patients with psoriasis, especially those with more severe skin disease**
- **Psoriasis may be an independent risk factor for diabetes and major adverse cardiovascular events; the risk of a major adverse cardiovascular event is greatest among those with severe psoriasis**
- **Chronic systemic, specifically vascular, inflammation may be increased in patients with psoriasis and may contribute to atherogenesis**

**Major adverse cardiovascular events**

Cardiovascular (CV) risk factors are prevalent among patients with psoriasis, and therefore an increased risk of CV disease (CVD) may be expected. However, in 2006, a large, population-based cohort study in the United Kingdom found that psoriasis was associated with an increased risk of MI, independent of traditional risk factors, such as body mass index (BMI), smoking, hypertension, diabetes, and dyslipidemia.<sup>11</sup> Moreover, a dose-response effect was shown, with stronger, more clinically significant risk in patients with more severe disease as defined by receipt of phototherapy or systemic therapies indicated for severe psoriasis. Subsequently, numerous epidemiologic studies have similarly suggested psoriasis to be an independent risk factor for MI, stroke, and death caused by CVD, collectively termed major adverse cardiovascular events (MACE). While a few studies have reported non-statistically significant associations between psoriasis and MACE,<sup>12-15</sup> as discussed in detail elsewhere,<sup>16-18</sup> results from these studies remain consistent with the larger body of work that have found statistically significant associations. To date, many of the studies have been summarized in ≥1 of 8 meta-analyses of psoriasis and CVD (Table I).<sup>19-26</sup> Two meta-analyses<sup>19,25</sup> specifically examined the risks of MI, stroke, and CV mortality according to psoriasis severity and reported the greatest risks to be among those with severe disease. Risk of MI among patients

with mild psoriasis was found to be significantly increased in both meta-analyses,<sup>19,25</sup> albeit to a lesser extent, suggesting that CV risk is not limited to those with severe disease. Longer duration of psoriasis has also been associated with increased risk of CVD.<sup>27,28</sup> Collectively, these data provide evidence for psoriasis as an independent risk factor for CVD.

Additional analyses have identified the clinical importance of and provided practical measures for the increased risk of MACE associated with psoriasis.<sup>29,30</sup> In a cohort study of severe psoriasis patients in the United Kingdom, Mehta et al<sup>29</sup> found the attributable risk of severe psoriasis on MACE over a 10-year period to be 6.2%. Importantly, in a study to determine the impact of psoriasis on the Framingham Risk Score (FRS), adding psoriasis to the FRS resulted in reclassification of a majority of patients to a higher CV risk category whereby 73% of patients at low risk were reclassified as intermediate risk and 53% of patients at intermediate risk were reclassified as high risk.<sup>31</sup> Putting the psoriasis-associated CV risk into context with other chronic inflammatory diseases, Ahlehoff et al<sup>30</sup> found the increased risk of MACE associated with severe psoriasis to be nearly identical to that conferred by diabetes alone. Similarly, a single observational study of patients with either rheumatoid arthritis (RA) or psoriasis suggests that patients treated with similar systemic treatments (eg, methotrexate) each have similarly elevated risks of MACE, independent of traditional risk factors.<sup>32</sup>

Shared pathophysiologic pathways between psoriasis and CVD, including chronic type 1 helper (T<sub>H</sub>1) T cell- and T<sub>H</sub>17-mediated inflammation,<sup>33-38</sup> monocyte and neutrophil modulation,<sup>39-41</sup> increased oxidative stress,<sup>35</sup> endothelial cell dysfunction,<sup>42</sup> increased uric acid,<sup>43,44</sup> angiogenesis,<sup>35</sup> and increased circulating microparticles<sup>45-48</sup> may explain the increased CVD risk associated with psoriasis. In addition, persistent pathophysiologic processes that drive psoriasis (eg, epidermal hyperproliferation, inflammation,<sup>49,50</sup> and angiogenesis) may also exert pleiotropic adverse effects on the CV system that contribute to atherogenesis. Mouse models of psoriasis have shown that chronic skin-specific inflammation has systemic effects, including arterial hypertension,<sup>51</sup> endothelial dysfunction,<sup>51</sup> and vascular inflammation and thrombosis.<sup>38</sup> Studies in psoriasis patients yield similarly consistent findings using [18F]-fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT), a sensitive tool for measuring vascular inflammation and visualizing macrophage activity in vivo. Aortic inflammation measured by PET/CT is a predictor of future CV events and has been shown

to rapidly decrease when patients are exposed to interventions known to lower CV risk (ie, statin therapy), making it an attractive surrogate endpoint to study.<sup>52</sup> Aortic inflammation has been observed to be increased in psoriasis patients in a manner that is independent of CV risk factors and correlates with severity of skin disease,<sup>53</sup> lending further support to the idea that inflammatory pathways in psoriasis exert systemic effects. Lastly, common genetics between psoriasis, diabetes, and CVD, such as CDKAL1, ApoE4, and others, have been suggested,<sup>54-64</sup> and genes relevant to metabolic disease and CVD have been found to be dysregulated in lesional skin and in the serum of psoriasis patients.<sup>64-66</sup> On the other hand, other work suggests that shared genetic pathways are unlikely to explain the association between psoriasis and CVD.<sup>67</sup>

### Obesity

Obesity is an independent risk factor for psoriasis. In studies of incident psoriasis,<sup>68-70</sup> the risk of psoriasis was found to increase with higher BMI.<sup>69</sup> A meta-analysis of 16 observational studies found a pooled odds ratio (OR) for the association between psoriasis and obesity to be 1.66 (95% confidence interval [CI], 1.46-1.89; [Table II](#)).<sup>71</sup> Among studies that accounted for psoriasis severity, generally defined by treatment patterns, the pooled ORs for the association between obesity and mild and severe psoriasis were 1.46 (95% CI, 1.17-1.82) and 2.23 (95% CI, 1.63-3.05), respectively. As further support for a relationship between psoriasis severity and obesity, Langan et al<sup>72</sup> performed a cross-sectional study of patients with psoriasis in the United Kingdom for whom information on body surface area (BSA) involvement by psoriasis was available and found a positive dose-dependent relationship between objective measures of psoriasis severity and obesity.<sup>72</sup>

### Hypertension

Hypertension is more prevalent among patients with versus without psoriasis. A meta-analysis of 24 observational studies found a pooled OR for the association between psoriasis and hypertension to be 1.58 (95% CI, 1.42-1.76).<sup>73</sup> The odds of hypertension among patients with psoriasis increased with greater disease severity with ORs of 1.30 (95% CI, 1.15-1.47) for mild and 1.49 (95% CI, 1.20-1.86) for severe psoriasis as defined by treatment patterns.<sup>42</sup> Two cohort studies also observed psoriasis to be associated with an increased risk of incident hypertension.<sup>74,75</sup>

Importantly, studies of patients with hypertension suggest more severe hypertension and poorly controlled blood pressure among patients with

**Table I.** Summary of systematic reviews and meta-analyses assessing the association between psoriasis and major adverse cardiovascular events

Study	Study dates	No. of studies	Total no. of patients		Outcome	Composite measure of association (95% CI)	
			Psoriasis	No psoriasis			
Armstrong et al <sup>19</sup> (2013)	January 1, 1980 to January 1, 2012	9	Mild: 201,239 Severe: 17,415	9,914,799	MACE: MI, stroke, and CV mortality	MI Mild psoriasis: RR 1.29 (1.02-1.63) Severe psoriasis: RR 1.70 (1.32-2.18)	Stroke Mild psoriasis: RR 1.12 (1.08-1.16) Severe psoriasis: RR 1.56 (1.32-1.84)
						CV mortality Mild psoriasis: RR 1.03 (0.86-1.25) Severe psoriasis: RR 1.39 (1.11-1.74)	
Gaeta et al <sup>20</sup> (2013)	NR	13	1,862,297	43,407,300	CV risk: MI, vascular disease, and mortality	Overall CV risk RR 1.24 (1.18-1.31)	MI RR 1.24 (1.11-1.39) Vascular disease RR 1.27 (1.12-1.43) Mortality RR 1.41 (0.97-2.04)
Gu et al <sup>21</sup> (2013)	1966 to October 2012	15	Total (psoriasis + no psoriasis): 6,230,774		MI, stroke, CVD, and CV mortality	MI RR 1.32 (1.13-1.55)	Stroke RR 1.26 (1.12-1.41) CVD RR 1.47 (1.30-1.60) CV mortality RR 1.33 (1.00-1.77)
Horreau et al <sup>22</sup> (2013)	1980 to December 211	33	324,650	5,309,087	MI, CAD, and stroke	MI RR—cohort: 1.25 (1.03-1.52); cross-sectional: 1.57 (1.08-2.27)	CAD RR—cohort: 1.20 (1.13-1.27); case-control: 1.84 (1.09-3.09); cross-sectional: 1.19 (1.14-1.24)
						Stroke Cohort: 1.02 (0.92-1.14); cross-sectional: 1.14 (1.08-1.19)	

Miller et al <sup>23</sup> (2013)*	Before October 25, 2012	75	503,686	29,686,694	CVD, IHD, cerebrovascular disease, and CV mortality		CVD OR 1.4 (1.2-1.7) IHD OR 1.5 (1.2-1.9) Cerebrovascular disease 1.1 (0.9-1.3) CV mortality 0.9 (0.4-2.2)
Pietrzak et al <sup>24</sup> (2013)	1960 to 2011	14	367,358	9,199,656	CV events: MI, IHD, cerebral ischemic stroke, and sudden cardiac death		OR 1.28 (1.18-1.38)
Samarasekera et al <sup>25</sup> (2013)	1974 to 2012	14	All: 488,315 Mild: 327,418 Severe: 12,854	10,024,815	MI, stroke, and CV mortality	All psoriasis: HR/IRR 1.40 (1.03-1.89)	MI Mild psoriasis: HR/IRR 1.34 (1.07-1.68) Severe psoriasis: HR/IRR 3.04 (0.65-14.35)
						All psoriasis: HR/IRR 1.13 (1.01-1.26)	Stroke Mild psoriasis: HR/IRR 1.15 (0.98-1.35) Severe psoriasis: HR/IRR 1.59 (1.34-1.89)
						All psoriasis: NR	CV mortality Mild psoriasis: SMR 1.03 (0.86-1.25) Severe psoriasis: SMR 1.37 (1.17-1.60); HR 1.57 (1.26-1.96)
Xu et al <sup>26</sup> (2012)	Database inception to March 2012	7	326,598	5,230,048	Composite of MI and stroke		Composite RR 1.20 (1.10-1.31) MI RR 1.22 (1.05-1.42) Stroke RR 1.21 (1.04-1.40)

CAD, Coronary artery disease; CHD, coronary heart disease; CV, cardiovascular; CVD, cardiovascular disease; HR, hazard ratio; IHD, ischemic heart disease; IRR, incidence rate ratio; MACE, major adverse cardiovascular event; MI, myocardial infarction; OR, odds ratio; RR, relative risk or risk ratio.

\*Systematic review and meta-analysis of the association between psoriasis and CVD and cardiovascular risk factors. Total numbers of studies and patients included are as reported in the full systematic review and meta-analysis, a subset of which is specifically relevant to psoriasis and CVD.

**Table II.** Summary of systematic reviews and meta-analyses assessing the association between psoriasis and cardiovascular disease risk factors

Study	Study dates	Total no. of patients		No. of studies included	CV risk factor	Composite measure of association (95% CI)
		Psoriasis	No psoriasis			
Armstrong et al <sup>71</sup> (2012)	January 1, 1980 to January 1, 2012	201,831	2,119,329	Total: 16 Severity assessment: 5 Incidence: 1	Obesity	Overall: OR 1.66 (1.46-1.89); mild: OR 1.46 (1.17-1.82); severe: OR 2.23 (1.63-3.05); incidence: HR 1.18 (1.14-1.23)
Armstrong et al <sup>73</sup> (2012)	January 1, 1980 to January 1, 2012	309,469	2,384,229	Total: 24 Severity assessment: 5 Incidence: 2	Hypertension	Overall: OR 1.58 (1.42-1.76); mild: OR 1.30 (1.15-1.47); severe: OR 1.49 (1.20-1.86); incidence: HR 1.09 (1.05-1.14); incidence: RR 1.17 (1.06-1.30)
Armstrong et al <sup>78</sup> (2012)	January 1, 1980 to January 1, 2012	404,494	4,640,847	Total: 27 Severity assessment: 5 Incidence: 5	Diabetes	Overall: OR 1.59 (1.38-1.83); mild: OR 1.53 (1.16-2.04); severe: OR 1.97 (1.48-2.62); incidence: RR 1.27 (1.16-1.40)
Ma et al <sup>81</sup> (2012) <sup>†</sup>	January 1, 1980 to January 1, 2012	265,685	2,167,198	Total: 25 Severity assessment: 5 Incidence: 1	Dyslipidemia	Overall OR: 1.04-5.55; mild OR: 1.10-3.38; severe OR: 1.26-5.55
Armstrong et al <sup>89</sup> (2013)	January 1, 1980 to January 1, 2012	41,853	1,357,324	Total: 12 Severity assessment: 3	Metabolic syndrome	Overall OR: 2.26 (1.70-3.01); mild OR: 1.22 (1.11-1.35)*; moderate OR: 1.56 (1.38-1.76)*; severe OR: 1.98 (1.62-2.43)*

CI, Confidence interval; CV, cardiovascular; HR, hazard ratio; OR, odds ratio; RR, relative risk.

\*Reported from single study by Langan et al.<sup>72</sup>

<sup>†</sup>Systematic review only.

psoriasis compared with those without psoriasis.<sup>76,77</sup> In addition, the likelihood of poorly controlled hypertension appears to increase with more severe skin disease, independent of BMI and other risk factors.<sup>77</sup>

### Diabetes

Psoriasis is associated with an increased risk of diabetes, independent of traditional risk factors. A meta-analysis of 5 cohort studies assessing the risk of incident diabetes among patients with psoriasis found a pooled relative risk (RR) for diabetes of 1.27 (95% CI, 1.16-1.40).<sup>78</sup> The risk of diabetes and likelihood of insulin resistance and diabetic complications are suggested to increase with greater psoriasis severity as defined by treatment patterns or BSA affected, respectively, independent of traditional risk factors, such as BMI.<sup>9,72,79</sup> Moreover, diabetic patients with psoriasis appear to be more likely to require pharmacologic management<sup>79</sup> and suffer from micro- and macrovascular diabetes complications than diabetic patients without psoriasis.<sup>80</sup>

### Dyslipidemia

Dyslipidemia may be more prevalent among patients with than without psoriasis. In a systematic review, 20 of 25 included studies found significant associations between psoriasis and dyslipidemia, with ORs ranging from 1.04 to 5.55.<sup>81</sup> Among 3 of the studies included in the systematic review, the ORs for dyslipidemia ranged from 1.10 to 3.38 for patients with mild psoriasis and from 1.36 to 5.55 for patients with severe psoriasis. The directionality of the association between the 2 conditions remains unclear; some studies suggest dyslipidemia may be a risk factor for developing psoriasis.<sup>82,83</sup>

Advanced lipid testing techniques have shown a more atherogenic lipid profile and decreased high density lipoprotein (HDL) cholesterol efflux capacity (CEC) among patients with versus without psoriasis, beyond CV risk factors.<sup>84,85</sup> Increasing psoriasis severity is negatively correlated with HDL CEC in both adults and children with psoriasis.<sup>85,86</sup> HDL CEC is also directly related to coronary artery disease burden in patients with psoriasis<sup>87</sup> and is suggested to be an important proxy for vascular disease.

### Metabolic syndrome

Metabolic syndrome is generally defined by the presence of a combination of central obesity, hypertension, insulin resistance, and dyslipidemia.<sup>88</sup> Studies have found metabolic syndrome and its individual components to be more prevalent among patients with than without psoriasis in both adult and pediatric populations.<sup>89,90</sup> A meta-analysis of 12 observational

studies found a pooled OR of 2.26 (95% CI, 1.70-3.01) for the association between psoriasis and metabolic syndrome, but the analysis was limited by the presence of publication bias due to an absence of smaller studies in the published literature.<sup>89</sup> Importantly, in Langan et al's cross-sectional study<sup>72</sup> in the United Kingdom, the prevalence of metabolic syndrome correlated directly with BSA affected by psoriasis.

## GASTROINTESTINAL DISEASE

### Key points

- **Psoriasis may be associated with an increased incidence and prevalence of inflammatory bowel disease, particularly Crohn's disease**
- **Few studies suggest that psoriasis is associated with an increased prevalence of hepatic diseases, particularly nonalcoholic fatty liver disease**

### Inflammatory bowel disease

Common genetic and inflammatory pathways have been implicated in psoriasis and IBD, which includes Crohn's disease (CD) and ulcerative colitis (UC).<sup>59,91-94</sup> The epidemiology of this relationship remains poorly defined. Several studies have observed increased prevalence and incidence of IBD among patients with psoriasis<sup>95,96</sup> and vice versa,<sup>97-99</sup> with varying degrees of association, and a Taiwanese study suggested an absence of association.<sup>10</sup> Cohen et al<sup>95</sup> observed that psoriasis may be more strongly associated with CD than UC (ORs 2.49 [95% CI, 1.71-3.62] and 1.64 [95% CI, 1.15-2.23], respectively). Similarly, a cohort study of US women found an increased risk of CD among patients with psoriasis (RR, 3.86 [95% CI, 2.23-6.67]), while the risk of UC was attenuated and not statistically significant (RR, 1.17 [95% CI, 0.41-3.36]).<sup>96</sup>

### Hepatic disease

Nonalcoholic fatty liver disease (NAFLD) is a common chronic liver disease in Western industrialized countries<sup>100</sup> and encompasses a spectrum of liver disorders from mild hepatic steatosis to nonalcoholic steatohepatitis (NASH). Associations between psoriasis and NAFLD have been reported in the literature. In a meta-analysis of 7 observational studies that were considered low to moderate quality and, for the most part, did not adjust for potential confounding factors, such as metabolic syndrome, NAFLD was found to be more prevalent among patients with versus without psoriasis (pooled OR, 2.15 [95% CI, 1.57-2.94]).<sup>101</sup> Beyond NAFLD, a cross-sectional study in the United Kingdom found that psoriasis was associated with a higher prevalence of

“mild” liver disease, including chronic hepatitis, alcoholic liver disease, and NAFLD (OR, 1.41 [95% CI, 1.12-1.76]).<sup>9</sup> A positive dose-response relationship between psoriasis severity based on BSA involvement and “mild” liver disease was also seen.

## CHRONIC KIDNEY DISEASE

### Key points

- **Moderate to severe psoriasis may be an independent risk factor for chronic kidney disease and end-stage renal disease**
- **The odds of chronic kidney disease increase in a dose-dependent manner with greater psoriasis severity**

The term “psoriatic nephropathy” was first introduced based on case reports of glomerulonephritides in patients with psoriasis.<sup>102</sup> Until recently, most studies assessing the association between psoriasis and kidney disease have been small and cross-sectional, with varying results. In a UK cohort study of cause-specific mortality among patients with psoriasis, severe psoriasis was associated with a 4-fold increased risk of death from nephritic or nonhypertensive kidney disease.<sup>103</sup> A Swedish cohort study also found mild psoriasis to be associated with more than a 2-fold increased risk of death from kidney disease.<sup>104</sup> In 2013, another UK cohort study found that severe psoriasis may, in fact, be a risk factor for chronic kidney disease (CKD) and end-stage renal disease (ESRD), independent of traditional risk factors, such as age, sex, BMI, CVD, diabetes, hypertension, hyperlipidemia, and nephrotoxic medications (hazard ratio [HR] for CKD 1.93 [95% CI, 1.79-2.08]; HR for ESRD, 4.15 [95% CI, 1.70-10.11]).<sup>105</sup> A nested cross-sectional analysis of patients with psoriasis for whom information on BSA involvement was available found the prevalence of CKD to increase in a dose-dependent manner with more severe psoriasis. A cohort study in Taiwan similarly found severe psoriasis to be associated with nearly 2- and 3-fold increased risks of CKD and ESRD, respectively.<sup>106</sup>

## MALIGNANCY

### Key points

- **Psoriasis, particularly severe disease, may be associated with an increased risk of cancer**
- **Lymphoma has been most consistently associated with psoriasis, and risk of cutaneous T-cell lymphoma is suggested to be the highest**

Patients receiving treatments for severe psoriasis have a 41% increased risk of dying from malignancy

than patients without psoriasis.<sup>103</sup> Risk of malignancy attributable to psoriasis itself remains uncertain. A meta-analysis of 11 observational studies evaluating the risk of malignancy among patients with psoriasis suggested that overall risk of cancer, excluding nonmelanoma skin cancers (NMSCs), is increased (standardized incidence ratio, 1.16 [95% CI, 1.07-1.25]).<sup>107</sup> Greater risks of upper aerodigestive tract, respiratory tract, liver, pancreas, urinary tract cancers, and lymphoma were also suggested.<sup>107</sup> The level of heterogeneity among the included studies was high, making interpretation challenging. In addition, many studies did not account for important confounding factors, such as smoking and drinking, or assess psoriasis treatment effects on the risk of subsequent malignancy, calling into question the validity of attributing the increased risk of cancer to psoriasis alone. A subsequent cohort study of cancer risk among patients with psoriasis in the United Kingdom that included information on BMI, smoking, and drinking also found increased risks of lung cancer, NMSC, and lymphoma, supporting some of Pouplard et al's findings.<sup>108</sup> The greatest risks of cancer were among those receiving treatments for severe psoriasis. The association between psoriasis and lung cancer was lost, however, after stratification by smoking status. Additional studies<sup>109-111</sup> assessing lymphoma risk in patients with psoriasis also found persistently increased risks of lymphoma (1.3- to 2-fold increased risk) even among those without a history of immunosuppressive therapy, although absolute risks remained low. Of the specific lymphoma types, the association between psoriasis and cutaneous T-cell lymphoma (CTCL) was suggested to be the strongest.<sup>108,111</sup> It remains unclear what role psoriasis therapies or misdiagnosis of CTCL as psoriasis may play in explaining this observation.

## INFECTION

### Key points

- **Streptococcal pharyngitis is a trigger of guttate psoriasis, and exacerbation of psoriasis in the setting of HIV infection is known**
- **Psoriasis may be associated with an increased risk of serious infection (ie, infection requiring hospitalization), especially respiratory infections**

Infection is the second-leading cause of excess death among patients who are receiving therapies for severe psoriasis, and patients with severe psoriasis have a 65% increased risk of dying from infection than patients without psoriasis.<sup>103</sup> With the advent of targeted biologic therapies, much attention has been

paid to measuring the risk of infection associated with these therapies for psoriasis. However, infection risk attributable to psoriasis itself remains poorly understood. The most well-recognized association between psoriasis and infection is that of guttate psoriasis and streptococcal pharyngitis, which is thought to be caused by molecular mimicry between streptococcal M peptides and human keratins.<sup>112,113</sup> Exacerbation of psoriasis in the setting of HIV infection has also been documented.<sup>114,115</sup> The risk of serious infection among patients with psoriasis has only more recently been evaluated.<sup>116,117</sup> A Dutch cohort study found psoriasis to be independently associated with an increased risk of serious infection (HR, 1.54 [95% CI, 1.44-1.65]) whereby the greatest risk was among patients with severe psoriasis as defined by treatment patterns (HR, 1.81 [95% CI, 1.57-2.08]).<sup>116</sup> Respiratory tract, abdominal, and skin infections were the most common infections among patients with psoriasis. Similarly, a cohort study in Taiwan reported an increased risk of hospitalized pneumonia among patients with psoriasis, independent of other potential risk factors for pneumonia (HR, 1.40 [95% CI, 1.12-1.73]). Severe psoriasis was associated with the greatest risk of hospitalized pneumonia (HR, 1.68 [95% CI, 1.12-2.52]).<sup>117</sup> While neither study had access to information on potential confounders, such as obesity, smoking, and drinking, subsequent cohort studies in the United Kingdom that included this information confirmed that psoriasis is associated with an increased risk of serious infection<sup>118</sup> including hospitalized pneumonia,<sup>119</sup> and further suggested that this risk may increase with greater BSA involvement by psoriasis.

## MOOD DISORDERS

### Key points

- **Mood disorders are common among patients with psoriasis**
- **Psoriasis is associated with an increased risk of depression, anxiety, and suicidal ideation**

Psoriasis has a major impact on patients' physical and emotional health-related quality of life comparable to other major illnesses,<sup>4</sup> and this may predispose patients to the development of mood disorders, such as depression, anxiety, and suicidality. Mood disorders, particularly depression, have been suggested to be more prevalent in patients with psoriasis than in the general population (up to 62% prevalence).<sup>120</sup> In a meta-analysis of 98 mostly cross-sectional studies examining the association between psoriasis and depression, patients with psoriasis had more depressive symptoms (pooled standardized mean difference, 1.16 [95% CI, 0.67-1.66]) and were

nearly 1.6-fold more likely to experience depression (pooled OR, 1.57 [95% CI, 1.40-1.76]) than patients without psoriasis.<sup>120</sup>

The risk of depression in psoriasis has been evaluated in 2 cohort studies. In a UK study, psoriasis was found to be associated with increased risks of depression (HR, 1.39 [95% CI, 1.37-1.41]), anxiety (HR, 1.31 [95% CI, 1.29-1.34]), and suicidality (HR, 1.44 [95% CI, 1.32-1.57]).<sup>121</sup> The risk of depression was greatest among patients who were receiving therapies for severe psoriasis (HR, 1.72 [95% CI, 1.57-1.88]). Similarly, a study of women in the Nurses' Health Study<sup>122</sup> found psoriasis to be associated with a nearly 30% increased risk of depression (RR, 1.29 [95% CI, 1.10-1.52]), independent of age, BMI, lifestyle factors, and comorbid conditions.

## PSORIATIC ARTHRITIS

### Key points

- **Psoriatic arthritis is an inflammatory arthritis that is present in 6% to 42% of patients with psoriasis**
- **Psoriatic arthritis is more prevalent among patients with more extensive skin disease**
- **Approximately 15% of patients with psoriasis have undiagnosed psoriatic arthritis**

Psoriatic arthritis (PsA) is the most well-recognized comorbidity of psoriasis and is a heterogeneous inflammatory arthritis characterized by joint or enthesal inflammation and extra-articular manifestations.<sup>123</sup> The prevalence of inflammatory arthritis in patients with psoriasis ranges from 6% to 42% depending on the definitions used and populations studied.<sup>124-137</sup> The prevalence of PsA increases with greater psoriasis severity<sup>124,132,138</sup> and duration<sup>124,139</sup>; however, the severity of skin disease is only weakly associated with severity of joint disease. PsA has been associated with the distribution of psoriasis involvement (ie, scalp, intergluteal, and perianal)<sup>140</sup> and the presence of nail dystrophy, which is suggested to indicate early enthesal inflammation.<sup>123,140,141</sup>

The diagnosis of PsA can be especially challenging. The differential diagnosis includes osteoarthritis, RA, crystal arthropathy (eg, gout or calcium pyrophosphate disease), and fibromyalgia.<sup>123,142-146</sup> Undiagnosed PsA among patients with psoriasis seen in the dermatology setting is prevalent and estimated at 15.5%.<sup>147</sup> PsA generally occurs after the onset of psoriasis<sup>141,147</sup> and can be progressive and result in permanent joint damage. Therefore, early detection is essential because early treatment improves outcomes.<sup>123,148,149</sup> The varied clinical features of and classification criteria for PsA

and its associations with cardiometabolic and other comorbid diseases are reviewed elsewhere.<sup>123,150</sup>

## EMERGING COMORBIDITIES

### Key point

- **Other emerging comorbidities of psoriasis include chronic obstructive pulmonary disease, peptic ulcer disease, sexual dysfunction, and obstructive sleep apnea**

Additional epidemiologic studies have suggested associations between psoriasis and other emerging comorbid conditions, including chronic obstructive pulmonary disease,<sup>9,151,152</sup> peptic ulcer disease,<sup>9,153</sup> sexual dysfunction,<sup>154</sup> and obstructive sleep apnea,<sup>155-157</sup> among others. Further characterization of known comorbidities and identification of new comorbid disease associations with psoriasis are anticipated as research efforts continue.

In summary, it is essential for both clinicians and patients to recognize the potentially heightened risk of CVD and other comorbidities associated with psoriasis that may increase with greater disease severity and duration. Particularly as psoriasis remains largely undertreated,<sup>158,159</sup> the disease remains active for decades in most patients, potentially placing them at increased risk for associated comorbidities and mortality. Patient and provider education and increased awareness of psoriasis comorbidities are critical to improving the care and quality of life for those living with psoriasis.

The authors thank Jina Chung, MD, for her early contributions to the preparation of the manuscript.

### REFERENCES

1. National Psoriasis Foundation. Available from: URL: [https://www.psoriasis.org/cure\\_known\\_statistics](https://www.psoriasis.org/cure_known_statistics). Accessed October 1, 2015.
2. Kurd SK, Gelfand JM. The prevalence of previously diagnosed and undiagnosed psoriasis in US adults: results from NHANES 2003-2004. *J Am Acad Dermatol*. 2009;60:218-224.
3. Rachakonda TD, Schupp CW, Armstrong AW. Psoriasis prevalence among adults in the United States. *J Am Acad Dermatol*. 2014;70:512-516.
4. Rapp SR, Feldman SR, Exum ML, et al. Psoriasis causes as much disability as other major medical diseases. *J Am Acad Dermatol*. 1999;41(3 pt 1):401-407.
5. Strauss H. Zur Lehre von der neurogenen und der thyreo-genen Glykosurie. *Dtsch Med Wochenschr*. 1897;20:309-312.
6. Reed WB, Becker SW, Rohde R, et al. Psoriasis and arthritis. Clinicopathologic study. *Arch Dermatol*. 1961;83:541-548.
7. McDonald CJ, Calabresi P. Psoriasis and occlusive vascular disease. *Br J Dermatol*. 1978;99:469-475.
8. Gelfand JM, Troxel AB, Lewis JD, et al. The risk of mortality in patients with psoriasis: results from a population-based study. *Arch Dermatol*. 2007;143:1493-1499.
9. Yeung H, Takeshita J, Mehta NN, et al. Psoriasis severity and the prevalence of major medical comorbidity: a population-based study. *JAMA Dermatol*. 2013;149:1173-1179.
10. Tsai TF, Wang TS, Hung ST, et al. Epidemiology and comorbidities of psoriasis patients in a national database in Taiwan. *J Dermatol Sci*. 2011;63:40-46.
11. Gelfand JM, Neimann AL, Shin DB, et al. Risk of myocardial infarction in patients with psoriasis. *JAMA*. 2006;296:1735-1741.
12. Brauchli YB, Jick SS, Miret M, et al. Psoriasis and risk of incident myocardial infarction, stroke or transient ischaemic attack: an inception cohort study with a nested case-control analysis. *Br J Dermatol*. 2009;160:1048-1056.
13. Wakkee M, Herings RM, Nijsten T. Psoriasis may not be an independent risk factor for acute ischemic heart disease hospitalizations: results of a large population-based Dutch cohort. *J Invest Dermatol*. 2010;130:962-967.
14. Dowlatshahi EA, Kavousi M, Nijsten T, et al. Psoriasis is not associated with atherosclerosis and incident cardiovascular events: the Rotterdam Study. *J Invest Dermatol*. 2013;133:2347-2354.
15. Parisi R, Rutter MK, Lunt M, et al. Psoriasis and the risk of major cardiovascular events: cohort study using the Clinical Practice Research Datalink. *J Invest Dermatol*. 2015;135:2189-2197.
16. Gelfand JM, Azfar RS, Mehta NN. Psoriasis and cardiovascular risk: strength in numbers. *J Invest Dermatol*. 2010;130:919-922.
17. Gelfand JM, Mehta NN, Langan SM. Psoriasis and cardiovascular risk: strength in numbers, part II. *J Invest Dermatol*. 2011;131:1007-1010.
18. Ogdie A, Troxel AB, Mehta NN, et al. Psoriasis and cardiovascular risk: strength in numbers part 3. *J Invest Dermatol*. 2015;135:2148-2150.
19. Armstrong EJ, Harskamp CT, Armstrong AW. Psoriasis and major adverse cardiovascular events: a systematic review and meta-analysis of observational studies. *J Am Heart Assoc*. 2013;2:e000062.
20. Gaeta M, Castelveccchio S, Ricci C, et al. Role of psoriasis as independent predictor of cardiovascular disease: a meta-regression analysis. *Int J Cardiol*. 2013;168:2282-2288.
21. Gu WJ, Weng CL, Zhao YT, Liu QH, Yin RX. Psoriasis and risk of cardiovascular disease: a meta-analysis of cohort studies. *Int J Cardiol*. 2013;168:4992-4996.
22. Horreau C, Pouplard C, Brenaut E, et al. Cardiovascular morbidity and mortality in psoriasis and psoriatic arthritis: a systematic literature review. *J Eur Acad Dermatol Venereol*. 2013;27(suppl 3):12-29.
23. Miller IM, Ellervik C, Yazdanyar S, et al. Meta-analysis of psoriasis, cardiovascular disease, and associated risk factors. *J Am Acad Dermatol*. 2013;69:1014-1024.
24. Pietrzak A, Bartosinska J, Chodorowska G, et al. Cardiovascular aspects of psoriasis: an updated review. *Int J Dermatol*. 2013;52:153-162.
25. Samarasekera EJ, Neilson JM, Warren RB, et al. Incidence of cardiovascular disease in individuals with psoriasis: a systematic review and meta-analysis. *J Invest Dermatol*. 2013;133:2340-2346.
26. Xu T, Zhang YH. Association of psoriasis with stroke and myocardial infarction: meta-analysis of cohort studies. *Br J Dermatol*. 2012;167:1345-1350.
27. Armstrong AW, Harskamp CT, Ledo L, et al. Coronary artery disease in patients with psoriasis referred for coronary angiography. *Am J Cardiol*. 2012;109:976-980.
28. Li WQ, Han JL, Manson JE, et al. Psoriasis and risk of nonfatal cardiovascular disease in U.S. women: a cohort study. *Br J Dermatol*. 2012;166:811-818.

29. Mehta NN, Yu Y, Pinnelas R, et al. Attributable risk estimate of severe psoriasis on major cardiovascular events. *Am J Med.* 2011;124:775.e1-775.e6.
30. Ahlehoff O, Gislason GH, Charlott M, et al. Psoriasis is associated with clinically significant cardiovascular risk: a Danish nationwide cohort study. *J Intern Med.* 2011;270:147-157.
31. Mehta NN, Krishnamoorthy P, Yu Y, et al. The impact of psoriasis on 10-year Framingham risk. *J Am Acad Dermatol.* 2012;67:796-798.
32. Ogdie A, Yu Y, Haynes K, et al. Risk of major cardiovascular events in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: a population-based cohort study. *Ann Rheum Dis.* 2015;74:326-332.
33. Nestle FO, Kaplan DH, Barker J. Psoriasis. *N Engl J Med.* 2009;361:496-509.
34. Packard RR, Lichtman AH, Libby P. Innate and adaptive immunity in atherosclerosis. *Semin Immunopathol.* 2009;31:5-22.
35. Armstrong AW, Voyles SV, Armstrong EJ, et al. Angiogenesis and oxidative stress: common mechanisms linking psoriasis with atherosclerosis. *J Dermatol Sci.* 2011;63:1-9.
36. Armstrong AW, Voyles SV, Armstrong EJ, et al. A tale of two plaques: convergent mechanisms of T-cell-mediated inflammation in psoriasis and atherosclerosis. *Exp Dermatol.* 2011;20:544-549.
37. Spah F. Inflammation in atherosclerosis and psoriasis: common pathogenic mechanisms and the potential for an integrated treatment approach. *Br J Dermatol.* 2008;159(suppl 2):10-17.
38. Wang Y, Gao H, Loyd CM, et al. Chronic skin-specific inflammation promotes vascular inflammation and thrombosis. *J Invest Dermatol.* 2012;132:2067-2075.
39. Davidovici BB, Sattar N, Prinz J, et al. Psoriasis and systemic inflammatory diseases: potential mechanistic links between skin disease and co-morbid conditions. *J Invest Dermatol.* 2010;130:1785-1796.
40. Mehta NN, Reilly MP. Monocyte mayhem: do subtypes modulate distinct atherosclerosis phenotypes? *Circ Cardiovasc Genet.* 2012;5:7-9.
41. Noels H, Weber C. Catching up with important players in atherosclerosis: type I interferons and neutrophils. *Curr Opin Lipidol.* 2011;22:144-145.
42. Alexandroff AB, Pauriah M, Camp RD, et al. More than skin deep: atherosclerosis as a systemic manifestation of psoriasis. *Br J Dermatol.* 2009;161:1-7.
43. Puig JG, Mateos FA, Jimenez ML, et al. Uric acid metabolism in psoriasis. *Adv Exp Med Biol.* 1986;195 Pt A:411-416.
44. Cassano N, Carbonara M, Panaro M, et al. Role of serum uric acid in conditioning the association of psoriasis with metabolic syndrome. *Eur J Dermatol.* 2011;21:808-809.
45. Martínez-Sales V, Vila V, Ricart JM, et al. Increased circulating endothelial cells and microparticles in patients with psoriasis. *Clin Hemorheol Microcirc.* 2015;60:283-290.
46. Pelletier F, Garnache-Ottou F, Angelot F, et al. Increased levels of circulating endothelial-derived microparticles and small-size platelet-derived microparticles in psoriasis. *J Invest Dermatol.* 2011;131:1573-1576.
47. Tamagawa-Mineoka R, Katoh N, Kishimoto S. Platelet activation in patients with psoriasis: increased plasma levels of platelet-derived microparticles and soluble P-selectin. *J Am Acad Dermatol.* 2010;62:621-626.
48. Takeshita J, Mohler ER, Krishnamoorthy P, et al. Endothelial cell-, platelet-, and monocyte/macrophage-derived microparticles are elevated in psoriasis beyond cardiometabolic risk factors. *J Am Heart Assoc.* 2014;3:e000507.
49. Rose S, Stansky E, Dagur PK, et al. Characterization of immune cells in psoriatic adipose tissue. *J Transl Med.* 2014;12:258.
50. Cheung L, Fisher RM, Kuzmina N, et al. Psoriasis skin inflammation-induced microRNA-26b targets NCEH1 in underlying subcutaneous adipose tissue. *J Invest Dermatol.* 2016;136:640-648.
51. Karbach S, Croxford AL, Oelze M, et al. Interleukin 17 drives vascular inflammation, endothelial dysfunction, and arterial hypertension in psoriasis-like skin disease. *Arterioscler Thromb Vasc Biol.* 2014;34:2658-2668.
52. Mehta NN, Yu Y, Saboury B, et al. Systemic and vascular inflammation in patients with moderate to severe psoriasis as measured by [18F]-fluorodeoxyglucose positron emission tomography-computed tomography (FDG-PET/CT): a pilot study. *Arch Dermatol.* 2011;147:1031-1039.
53. Naik HB, Natarajan B, Stansky E, et al. Severity of psoriasis associates with aortic vascular inflammation detected by FDG PET/CT and neutrophil activation in a prospective observational study. *Arterioscler Thromb Vasc Biol.* 2015;35:2667-2676.
54. Bowden DW, Rudock M, Ziegler J, et al. Coincident linkage of type 2 diabetes, metabolic syndrome, and measures of cardiovascular disease in a genome scan of the diabetes heart study. *Diabetes.* 2006;55:1985-1995.
55. Parker A, Meyer J, Lewitzky S, et al. A gene conferring susceptibility to type 2 diabetes in conjunction with obesity is located on chromosome 18p11. *Diabetes.* 2001;50:675-680.
56. Park MH, Kwak SH, Kim KJ, et al. Identification of a genetic locus on chromosome 4q34-35 for type 2 diabetes with overweight. *Exp Mol Med.* 2013;45:e7.
57. Ng MC, So WY, Lam VK, et al. Genome-wide scan for metabolic syndrome and related quantitative traits in Hong Kong Chinese and confirmation of a susceptibility locus on chromosome 1q21-q25. *Diabetes.* 2004;53:2676-2683.
58. Ng MC, So WY, Cox NJ, et al. Genome-wide scan for type 2 diabetes loci in Hong Kong Chinese and confirmation of a susceptibility locus on chromosome 1q21-q25. *Diabetes.* 2004;53:1609-1613.
59. Wolf N, Quaranta M, Prescott NJ, et al. Psoriasis is associated with pleiotropic susceptibility loci identified in type II diabetes and Crohn disease. *J Med Genet.* 2008;45:114-116.
60. Campalani E, Allen MH, Fairhurst D, et al. Apolipoprotein E gene polymorphisms are associated with psoriasis but do not determine disease response to acitretin. *Br J Dermatol.* 2006;154:345-352.
61. Nair RP, Ruether A, Stuart PE, et al. Polymorphisms of the IL12B and IL23R genes are associated with psoriasis. *J Invest Dermatol.* 2008;128:1653-1661.
62. Genetic Analysis of Psoriasis Consortium & the Wellcome Trust Case Control Consortium 2, Strange A, Capon F, Spencer CC, et al. A genome-wide association study identifies new psoriasis susceptibility loci and an interaction between HLA-C and ERAP1. *Nat Genet.* 2010;42:985-990.
63. Fung EY, Smyth DJ, Howson JM, et al. Analysis of 17 autoimmune disease-associated variants in type 1 diabetes identifies 6q23/TNFAIP3 as a susceptibility locus. *Genes Immun.* 2009;10:188-191.
64. Suarez-Farinas M, Li K, Fuentes-Duculan J, et al. Expanding the psoriasis disease profile: interrogation of the skin and serum of patients with moderate-to-severe psoriasis. *J Invest Dermatol.* 2012;132:2552-2564.
65. Eiris N, Gonzalez-Lara L, Santos-Juanes J, et al. Genetic variation at IL12B, IL23R and IL23A is associated with psoriasis severity, psoriatic arthritis and type 2 diabetes mellitus. *J Dermatol Sci.* 2014;75:167-172.

66. Mehta NN, Li K, Szapary P, et al. Modulation of cardiometabolic pathways in skin and serum from patients with psoriasis. *J Transl Med.* 2013;11:194.
67. Koch M, Baurecht H, Ried JS, et al. Psoriasis and cardiometabolic traits: modest association but distinct genetic architectures. *J Invest Dermatol.* 2015;135:1283-1293.
68. Setty AR, Curhan G, Choi HK. Obesity, waist circumference, weight change, and the risk of psoriasis in women: Nurses' Health Study II. *Arch Intern Med.* 2007;167:1670-1675.
69. Kumar S, Han J, Li T, et al. Obesity, waist circumference, weight change and the risk of psoriasis in US women. *J Eur Acad Dermatol Venereol.* 2013;27:1293-1298.
70. Naldi L, Chatenoud L, Linder D, et al. Cigarette smoking, body mass index, and stressful life events as risk factors for psoriasis: results from an Italian case-control study. *J Invest Dermatol.* 2005;125:61-67.
71. Armstrong AW, Harskamp CT, Armstrong EJ. The association between psoriasis and obesity: a systematic review and meta-analysis of observational studies. *Nutr Diabetes.* 2012;2:e54.
72. Langan SM, Seminara NM, Shin DB, et al. Prevalence of metabolic syndrome in patients with psoriasis: a population-based study in the United Kingdom. *J Invest Dermatol.* 2012;132(3 pt 1):556-562.
73. Armstrong AW, Harskamp CT, Armstrong EJ. The association between psoriasis and hypertension: a systematic review and meta-analysis of observational studies. *J Hypertens.* 2013;31:433-442.
74. Qureshi AA, Choi HK, Setty AR, et al. Psoriasis and the risk of diabetes and hypertension: a prospective study of US female nurses. *Arch Dermatol.* 2009;145:379-382.
75. Kaye JA, Li L, Jick SS. Incidence of risk factors for myocardial infarction and other vascular diseases in patients with psoriasis. *Br J Dermatol.* 2008;159:895-902.
76. Armstrong AW, Lin SW, Chambers CJ, et al. Psoriasis and hypertension severity: results from a case-control study. *PLoS ONE.* 2011;6:e18227.
77. Takeshita J, Wang S, Shin DB, et al. Effect of psoriasis severity on hypertension control: a population-based study in the United Kingdom. *JAMA Dermatol.* 2015;151:161-169.
78. Armstrong AW, Harskamp CT, Armstrong EJ. Psoriasis and the risk of diabetes mellitus: a systematic review and meta-analysis. *JAMA Dermatol.* 2013;149:84-91.
79. Azfar RS, Seminara NM, Shin DB, et al. Increased risk of diabetes mellitus and likelihood of receiving diabetes mellitus treatment in patients with psoriasis. *Arch Dermatol.* 2012;148:995-1000.
80. Armstrong AW, Guerin A, Sundaram M, et al. Psoriasis and risk of diabetes-associated microvascular and macrovascular complications. *J Am Acad Dermatol.* 2015;72:968-977.e2.
81. Ma C, Harskamp CT, Armstrong EJ, et al. The association between psoriasis and dyslipidaemia: a systematic review. *Br J Dermatol.* 2013;168:486-495.
82. Wu S, Li WQ, Han J, et al. Hypercholesterolemia and risk of incident psoriasis and psoriatic arthritis in US women. *Arthritis Rheum.* 2014;66:304-310.
83. Mallbris L, Granath F, Hamsten A, et al. Psoriasis is associated with lipid abnormalities at the onset of skin disease. *J Am Acad Dermatol.* 2006;54:614-621.
84. Mehta NN, Li R, Krishnamoorthy P, et al. Abnormal lipoprotein particles and cholesterol efflux capacity in patients with psoriasis. *Atherosclerosis.* 2012;224:218-221.
85. Holzer M, Wolf P, Curcic S, et al. Psoriasis alters HDL composition and cholesterol efflux capacity. *J Lipid Res.* 2012;53:1618-1624.
86. Tom WL, Playford MP, Admani S, et al. Characterization of lipoprotein composition and function in pediatric psoriasis reveals a more atherogenic profile. *J Invest Dermatol.* 2016;136:67-73.
87. Salahuddin T, Natarajan B, Playford MP, et al. Cholesterol efflux capacity in humans with psoriasis is inversely related to non-calcified burden of coronary atherosclerosis. *Eur Heart J.* 2015;36:2662-2665.
88. Kassi E, Pervanidou P, Kaltsas G, et al. Metabolic syndrome: definitions and controversies. *BMC Med.* 2011;9:48.
89. Armstrong AW, Harskamp CT, Armstrong EJ. Psoriasis and metabolic syndrome: a systematic review and meta-analysis of observational studies. *J Am Acad Dermatol.* 2013;68:654-662.
90. Gutmark-Little I, Shah KN. Obesity and the metabolic syndrome in pediatric psoriasis. *Clin Dermatol.* 2015;33:305-315.
91. Najarian DJ, Gottlieb AB. Connections between psoriasis and Crohn's disease. *J Am Acad Dermatol.* 2003;48:805-821.
92. Skroza N, Proietti I, Pampena R, et al. Correlations between psoriasis and inflammatory bowel diseases. *Biomed Res Int.* 2013;2013:983902.
93. Wellcome Trust Case Control Consortium. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. *Nature.* 2007;447:661-678.
94. Ellinghaus D, Ellinghaus E, Nair RP, et al. Combined analysis of genome-wide association studies for Crohn disease and psoriasis identifies seven shared susceptibility loci. *Am J Hum Genet.* 2012;90:636-647.
95. Cohen AD, Dreier J, Birkenfeld S. Psoriasis associated with ulcerative colitis and Crohn's disease. *J Eur Acad Dermatol Venereol.* 2009;23:561-565.
96. Li WQ, Han JL, Chan AT, et al. Psoriasis, psoriatic arthritis and increased risk of incident Crohn's disease in U.S. women. *Ann Rheum Dis.* 2013;72:1200-1205.
97. Bernstein CN, Wajda A, Blanchard JF. The clustering of other chronic inflammatory diseases in inflammatory bowel disease: a population-based study. *Gastroenterology.* 2005;129:827-836.
98. Yates VM, Watkinson G, Kelman A. Further evidence of an association between psoriasis, Crohn's disease and ulcerative colitis. *Br J Dermatol.* 1982;106:323-330.
99. Lee FI, Bellary SV, Francis C. Increased occurrence of psoriasis in patients with Crohn's disease and their relatives. *Am J Gastroenterol.* 1990;85:962-963.
100. Younossi ZM, Stepanova M, Afendy M, et al. Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008. *Clin Gastroenterol Hepatol.* 2011;9:524-530.e521.
101. Candia R, Ruiz A, Torres-Robles R, et al. Risk of non-alcoholic fatty liver disease in patients with psoriasis: a systematic review and meta-analysis. *J Eur Acad Dermatol Venereol.* 2015;29:656-662.
102. Singh NP, Prakash A, Kubba S, et al. Psoriatic nephropathy—does an entity exist? *Ren Fail.* 2005;27:123-127.
103. Abuabara K, Azfar RS, Shin DB, et al. Cause-specific mortality in patients with severe psoriasis: a population-based cohort study in the U.K. *Br J Dermatol.* 2010;163:586-592.
104. Svedbom A, Dalen J, Mamolo C, et al. Increased cause-specific mortality in patients with mild and severe psoriasis: a population-based Swedish register study. *Acta Derm Venereol.* 2015;95:809-815.
105. Wan J, Wang S, Haynes K, et al. Risk of moderate to advanced kidney disease in patients with psoriasis: population based cohort study. *Br J Dermatol.* 2013;347:f5961.

106. Chi CC, Wang J, Chen YF, et al. Risk of incident chronic kidney disease and end-stage renal disease in patients with psoriasis: a nationwide population-based cohort study. *J Dermatol Sci*. 2015;78:232-238.
107. Pouplard C, Brenaut E, Horreau C, et al. Risk of cancer in psoriasis: a systematic review and meta-analysis of epidemiological studies. *J Eur Acad Dermatol Venereol*. 2013;27(suppl 3):36-46.
108. Chiesa Fuxench ZC, Shin DB, Ogdie Beatty A, et al. The risk of cancer in patients with psoriasis: a population-based cohort study in The Health Improvement Network. *JAMA Dermatol*. 2016;152:282-290.
109. Brauchli YB, Jick SS, Miret M, et al. Psoriasis and risk of incident cancer: an inception cohort study with a nested case-control analysis. *J Invest Dermatol*. 2009;129:2604-2612.
110. Margolis D, Bilker W, Hennessy S, et al. The risk of malignancy associated with psoriasis. *Arch Dermatol*. 2001;137:778-783.
111. Gelfand JM, Shin DB, Neimann AL, et al. The risk of lymphoma in patients with psoriasis. *J Invest Dermatol*. 2006;126:2194-2201.
112. Naldi L, Peli L, Parazzini F, et al. Family history of psoriasis, stressful life events, and recent infectious disease are risk factors for a first episode of acute guttate psoriasis: results of a case-control study. *J Am Acad Dermatol*. 2001;44:433-438.
113. Telfer NR, Chalmers RJ, Whale K, et al. The role of streptococcal infection in the initiation of guttate psoriasis. *Arch Dermatol*. 1992;128:39-42.
114. Patel RV, Weinberg JM. Psoriasis in the patient with human immunodeficiency virus, part 1: review of pathogenesis. *Cutis*. 2008;82:117-122.
115. Morar N, Willis-Owen SA, Maurer T, et al. HIV-associated psoriasis: pathogenesis, clinical features, and management. *Lancet Infect Dis*. 2010;10:470-478.
116. Wakkee M, de Vries E, van den Haak P, et al. Increased risk of infectious disease requiring hospitalization among patients with psoriasis: a population-based cohort. *J Am Acad Dermatol*. 2011;65:1135-1144.
117. Kao LT, Lee CZ, Liu SP, et al. Psoriasis and the risk of pneumonia: a population-based study. *PLoS ONE*. 2014;9:e116077.
118. Takeshita J, Shin DB, Ogdie A, Gelfand JM. Increased risk of serious infection among patients with psoriasis: a population-based cohort study in the United Kingdom. *J Invest Dermatol*. 2016;136(5 suppl 1):S34.
119. Takeshita J, Shin DB, Ogdie A, Gelfand JM. Increased risk of pneumonia among patients with psoriasis: a population-based cohort study in the United Kingdom. *J Invest Dermatol*. 2015;135(5 suppl 1):S50.
120. Dowlatshahi EA, Wakkee M, Arends LR, et al. The prevalence and odds of depressive symptoms and clinical depression in psoriasis patients: a systematic review and meta-analysis. *J Invest Dermatol*. 2014;134:1542-1551.
121. Kurd SK, Troxel AB, Crits-Christoph P, et al. The risk of depression, anxiety, and suicidality in patients with psoriasis: a population-based cohort study. *Arch Dermatol*. 2010;146:891-895.
122. Dommasch ED, Li T, Okereke OI, et al. Risk of depression in women with psoriasis: a cohort study. *Br J Dermatol*. 2015;173:975-980.
123. Ogdie A, Weiss P. The epidemiology of psoriatic arthritis. *Rheum Dis Clin North Am*. 2015;41:545-568.
124. Ogdie A, Langan S, Love T, et al. Prevalence and treatment patterns of psoriatic arthritis in the UK. *Rheumatology (Oxford)*. 2013;52:568-575.
125. Li R, Sun J, Ren LM, et al. Epidemiology of eight common rheumatic diseases in China: a large-scale cross-sectional survey in Beijing. *Rheumatology (Oxford)*. 2012;51:721-729.
126. Yang Q, Qu L, Tian H, et al. Prevalence and characteristics of psoriatic arthritis in Chinese patients with psoriasis. *J Eur Acad Dermatol Venereol*. 2011;25:1409-1414.
127. Carneiro JN, Paula AP, Martins GA. Psoriatic arthritis in patients with psoriasis: evaluation of clinical and epidemiological features in 133 patients followed at the University Hospital of Brasília. *An Bras Dermatol*. 2012;87:539-544.
128. Henes JC, Ziupa E, Eisfelder M, et al. High prevalence of psoriatic arthritis in dermatological patients with psoriasis: a cross-sectional study. *Rheumatol Int*. 2014;34:227-234.
129. Ibrahim G, Waxman R, Helliwell PS. The prevalence of psoriatic arthritis in people with psoriasis. *Arthritis Rheum*. 2009;61:1373-1378.
130. Jamshidi F, Bouzari N, Seirafi H, et al. The prevalence of psoriatic arthritis in psoriatic patients in Tehran, Iran. *Arch Iran Med*. 2008;11:162-165.
131. Love TJ, Gudbjornsson B, Gudjonsson JE, et al. Psoriatic arthritis in Reykjavik, Iceland: prevalence, demographics, and disease course. *J Rheumatol*. 2007;34:2082-2088.
132. Haroon M, Kirby B, FitzGerald O. High prevalence of psoriatic arthritis in patients with severe psoriasis with suboptimal performance of screening questionnaires. *Ann Rheum Dis*. 2013;72:736-740.
133. Love TJ, Gudjonsson JE, Valdimarsson H, et al. Psoriatic arthritis and onycholysis — results from the cross-sectional Reykjavik psoriatic arthritis study. *J Rheumatol*. 2012;39:1441-1444.
134. Mease PJ, Gladman DD, Papp KA, et al. Prevalence of rheumatologist-diagnosed psoriatic arthritis in patients with psoriasis in European/North American dermatology clinics. *J Am Acad Dermatol*. 2013;69:729-735.
135. Khraishi M, Chouela E, Bejar M, et al. High prevalence of psoriatic arthritis in a cohort of patients with psoriasis seen in a dermatology practice. *J Cutan Med Surg*. 2012;16:122-127.
136. Radtke MA, Reich K, Blome C, et al. Prevalence and clinical features of psoriatic arthritis and joint complaints in 2009 patients with psoriasis: results of a German national survey. *J Eur Acad Dermatol Venereol*. 2009;23:683-691.
137. Reich K, Kruger K, Mossner R, et al. Epidemiology and clinical pattern of psoriatic arthritis in Germany: a prospective interdisciplinary epidemiological study of 1511 patients with plaque-type psoriasis. *Br J Dermatol*. 2009;160:1040-1047.
138. Tey HL, Ee HL, Tan AS, et al. Risk factors associated with having psoriatic arthritis in patients with cutaneous psoriasis. *J Dermatol*. 2010;37:426-430.
139. Ficco HM, Citera G, Cocco JA. Prevalence of psoriatic arthritis in psoriasis patients according to newer classification criteria. *Clin Rheumatol*. 2014;33:1489-1493.
140. Wilson FC, Icen M, Crowson CS, et al. Incidence and clinical predictors of psoriatic arthritis in patients with psoriasis: a population-based study. *Arthritis Rheum*. 2009;61:233-239.
141. Raposo I, Torres T. Nail psoriasis as a predictor of the development of psoriatic arthritis. *Actas Dermosifiliogr*. 2015;106:452-457.
142. Merola JF, Wu S, Han J, et al. Psoriasis, psoriatic arthritis and risk of gout in US men and women. *Ann Rheum Dis*. 2015;74:1495-1500.
143. Mody E, Husni ME, Schur P, et al. Multidisciplinary evaluation of patients with psoriasis presenting with musculoskeletal pain: a dermatology: rheumatology clinic experience. *Br J Dermatol*. 2007;157:1050-1051.

144. Marchesoni A, Atzeni F, Spadaro A, et al. Identification of the clinical features distinguishing psoriatic arthritis and fibromyalgia. *J Rheumatol*. 2012;39:849-855.
145. De Marco G, Cattaneo A, Battafarano N, et al. Not simply a matter of psoriatic arthritis: epidemiology of rheumatic diseases in psoriatic patients. *Arch Dermatol Res*. 2012;304:719-726.
146. Tan AL, Grainger AJ, Tanner SF, et al. A high-resolution magnetic resonance imaging study of distal interphalangeal joint arthropathy in psoriatic arthritis and osteoarthritis: are they the same? *Arthritis Rheum*. 2006;54:1328-1333.
147. Villani AP, Rouzaud M, Sevrain M, et al. Prevalence of undiagnosed psoriatic arthritis among psoriasis patients: systematic review and meta-analysis. *J Am Acad Dermatol*. 2015;73:242-248.
148. Gladman DD, Thavaneswaran A, Chandran V, et al. Do patients with psoriatic arthritis who present early fare better than those presenting later in the disease? *Ann Rheum Dis*. 2011;70:2152-2154.
149. Theander E, Husmark T, Alenius GM, et al. Early psoriatic arthritis: short symptom duration, male gender and preserved physical functioning at presentation predict favourable outcome at 5-year follow-up. Results from the Swedish Early Psoriatic Arthritis Register (SwePsA). *Ann Rheum Dis*. 2014;73:407-413.
150. Ogdie A, Schwartzman S, Husni ME. Recognizing and managing comorbidities in psoriatic arthritis. *Curr Opin Rheumatol*. 2015;27:118-126.
151. Dreiherr J, Weitzman D, Shapiro J, et al. Psoriasis and chronic obstructive pulmonary disease: a case-control study. *Br J Dermatol*. 2008;159:956-960.
152. Chiang YY, Lin HW. Association between psoriasis and chronic obstructive pulmonary disease: a population-based study in Taiwan. *J Eur Acad Dermatol Venereol*. 2012;26:59-65.
153. Yang YW, Keller JJ, Lin HC. Medical comorbidity associated with psoriasis in adults: a population-based study. *Br J Dermatol*. 2011;165:1037-1043.
154. Molina-Leyva A, Jimenez-Moleon JJ, Naranjo-Sintes R, et al. Sexual dysfunction in psoriasis: a systematic review. *J Eur Acad Dermatol Venereol*. 2015;29:649-655.
155. Papadavid E, Vlami K, Dalamaga M, et al. Sleep apnea as a comorbidity in obese psoriasis patients: a cross-sectional study. Do psoriasis characteristics and metabolic parameters play a role? *J Eur Acad Dermatol Venereol*. 2013;27:820-826.
156. Yang YW, Kang JH, Lin HC. Increased risk of psoriasis following obstructive sleep apnea: a longitudinal population-based study. *Sleep Med*. 2012;13:285-289.
157. Cohen JM, Jackson CL, Li TY, et al. Sleep disordered breathing and the risk of psoriasis among US women. *Arch Dermatol Res*. 2015;307:433-438.
158. Horn EJ, Fox KM, Patel V, et al. Are patients with psoriasis undertreated? Results of National Psoriasis Foundation survey. *J Am Acad Dermatol*. 2007;57:957-962.
159. Armstrong AW, Robertson AD, Wu J, Schupp C, Lebwohl MG. Undertreatment, treatment trends, and treatment dissatisfaction among patients with psoriasis and psoriatic arthritis in the United States: findings from the National Psoriasis Foundation surveys, 2003-2011. *JAMA Dermatol*. 2013;149:1180-1185.